| pubmed-article:12366662 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12366662 | lifeskim:mentions | umls-concept:C0042149 | lld:lifeskim |
| pubmed-article:12366662 | lifeskim:mentions | umls-concept:C0334359 | lld:lifeskim |
| pubmed-article:12366662 | lifeskim:mentions | umls-concept:C0038952 | lld:lifeskim |
| pubmed-article:12366662 | lifeskim:mentions | umls-concept:C0543478 | lld:lifeskim |
| pubmed-article:12366662 | lifeskim:mentions | umls-concept:C0441771 | lld:lifeskim |
| pubmed-article:12366662 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:12366662 | pubmed:dateCreated | 2002-10-7 | lld:pubmed |
| pubmed-article:12366662 | pubmed:abstractText | The objective of this study was to assess the impact of surgical cytoreduction on the survival of patients with uterine papillary serous carcinoma (UPSC). Patients added to the institutional tumor registries between January 1980 and September 2001 with the diagnosis of UPSC were reviewed. The records of 43 patients who underwent surgical cytoreduction for FIGO stage III and IV disease were reviewed. The median survival of UPSC patients with microscopic residual disease was significantly improved compared to those with macroscopic residual disease following primary surgical cytoreduction. We conclude that primary surgical cytoreduction resulting in microscopic residual disease is associated with an improvement in recurrence-free survival and overall survival in women with UPSC. | lld:pubmed |
| pubmed-article:12366662 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12366662 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12366662 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12366662 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12366662 | pubmed:issn | 1048-891X | lld:pubmed |
| pubmed-article:12366662 | pubmed:author | pubmed-author:JonesN LNL | lld:pubmed |
| pubmed-article:12366662 | pubmed:author | pubmed-author:FuY SYS | lld:pubmed |
| pubmed-article:12366662 | pubmed:author | pubmed-author:BerekJ SJS | lld:pubmed |
| pubmed-article:12366662 | pubmed:author | pubmed-author:Farias-Eisner... | lld:pubmed |
| pubmed-article:12366662 | pubmed:author | pubmed-author:KarlanB YBY | lld:pubmed |
| pubmed-article:12366662 | pubmed:author | pubmed-author:HolschneiderC... | lld:pubmed |
| pubmed-article:12366662 | pubmed:author | pubmed-author:MemarzadehSS | lld:pubmed |
| pubmed-article:12366662 | pubmed:author | pubmed-author:BristowR ERE | lld:pubmed |
| pubmed-article:12366662 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12366662 | pubmed:volume | 12 | lld:pubmed |
| pubmed-article:12366662 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12366662 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12366662 | pubmed:pagination | 454-8 | lld:pubmed |
| pubmed-article:12366662 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:12366662 | pubmed:meshHeading | pubmed-meshheading:12366662... | lld:pubmed |
| pubmed-article:12366662 | pubmed:meshHeading | pubmed-meshheading:12366662... | lld:pubmed |
| pubmed-article:12366662 | pubmed:meshHeading | pubmed-meshheading:12366662... | lld:pubmed |
| pubmed-article:12366662 | pubmed:meshHeading | pubmed-meshheading:12366662... | lld:pubmed |
| pubmed-article:12366662 | pubmed:meshHeading | pubmed-meshheading:12366662... | lld:pubmed |
| pubmed-article:12366662 | pubmed:meshHeading | pubmed-meshheading:12366662... | lld:pubmed |
| pubmed-article:12366662 | pubmed:meshHeading | pubmed-meshheading:12366662... | lld:pubmed |
| pubmed-article:12366662 | pubmed:meshHeading | pubmed-meshheading:12366662... | lld:pubmed |
| pubmed-article:12366662 | pubmed:meshHeading | pubmed-meshheading:12366662... | lld:pubmed |
| pubmed-article:12366662 | pubmed:meshHeading | pubmed-meshheading:12366662... | lld:pubmed |
| pubmed-article:12366662 | pubmed:meshHeading | pubmed-meshheading:12366662... | lld:pubmed |
| pubmed-article:12366662 | pubmed:meshHeading | pubmed-meshheading:12366662... | lld:pubmed |
| pubmed-article:12366662 | pubmed:meshHeading | pubmed-meshheading:12366662... | lld:pubmed |
| pubmed-article:12366662 | pubmed:meshHeading | pubmed-meshheading:12366662... | lld:pubmed |
| pubmed-article:12366662 | pubmed:meshHeading | pubmed-meshheading:12366662... | lld:pubmed |
| pubmed-article:12366662 | pubmed:meshHeading | pubmed-meshheading:12366662... | lld:pubmed |
| pubmed-article:12366662 | pubmed:meshHeading | pubmed-meshheading:12366662... | lld:pubmed |
| pubmed-article:12366662 | pubmed:meshHeading | pubmed-meshheading:12366662... | lld:pubmed |
| pubmed-article:12366662 | pubmed:meshHeading | pubmed-meshheading:12366662... | lld:pubmed |
| pubmed-article:12366662 | pubmed:meshHeading | pubmed-meshheading:12366662... | lld:pubmed |
| pubmed-article:12366662 | pubmed:articleTitle | FIGO stage III and IV uterine papillary serous carcinoma: impact of residual disease on survival. | lld:pubmed |
| pubmed-article:12366662 | pubmed:affiliation | Division of Gynecologic Oncology, UCLA School of Medicine, Los Angeles, California 90095-1740, USA. | lld:pubmed |
| pubmed-article:12366662 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12366662 | pubmed:publicationType | Comparative Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12366662 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12366662 | lld:pubmed |
